GlobeNewswire Inc.··NaOlema Oncology Advances Breast Cancer Pipeline, Secures $218.5M in Funding
Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.
PFEOLMAPhase 3 trialsclinical development